RNAi Firms Stake Their Claims First there was gene splicing. Next came monoclonal antibodies. And now, RNA interference, or gene silencing, has taken the scientific community by storm. Reportedly, RNA interference technology has revolutionized the practice of molecular biology – and the excitement it has generated continues to mount
More U.S. Investment in Biotech Needed, USAID Chief Says The United States and the international community should continue to invest more in the development of new agricultural technologies — including biotechnology — to prevent millions more Africans from becoming malnourished and vulnerable to disease and infection, says Andrew Natsios, administrator of the U.S. Agency for International Development (USAID).
Wake Up and Smell the Science
Longer-Lasting Perfume Is One Promise As Biotechnology Heads for Store Shelves
Biotech Investors: When Will They Ever Learn?
Investors should get a grip on reality. Many small companies that were lifted on the latest news are strapped for cash and pursuing risky science that will take years to bear fruit. Even for big players, good trial data on a drug don’t guarantee Food & Drug Administration approval. And once drugs do get approved, most of them face competition in the market.
Drug ads deliver a few side effects Drug companies tripled their advertising budgets in recent years to acquaint American consumers with things like acid reflux disease, depression, erectile dysfunction, and even toenail fungus, a marketing blitz that accounted for roughly 12 percent of the growth in national prescription drug spending in 2000, according to a Harvard University-MIT study released yesterday.
Biotech Industry Could Turn Profitable This Decade
The U.S. biotechnology industry could turn a net profit within five to seven years if it gets a break on both regulatory and technological fronts, the author of a new report on the industry said.
Biotech firms eye rally hungrily
With so many firms in dire financial straits, many executives are desperately hoping that this spring’s rally in biotech stocks will give way to a turnaround that will allow them to raise the cash they need to survive.
Biotech Stock Report – WOW! The market has gotten ahead of itself by chasing stories, but there is, in fact, fundamental improvement in the outlook for the biotech business. Wall Street is anticipating a slough of new products to hit the market in 2003/2004 and biotechs will be rewarded with earnings/profits.
Schering-Plough: Drugmaker, Heal Thyself
It has a potential blockbuster and a savvy new CEO. With federal probers and Claritin’s expired patent to deal with, it will need both
Geron’s the Biotech of the Day
Geron saw its shares rise $1.72, or 25%, to $8.68 after the company said it has received a patent that could be used in stem-cell research. The process would be used, if it’s ever needed, to provide an additional level of safety for cell therapies made from human embryonic stem cells, the company said.